CONCERT PLUS: An Open-Label Extension of the CONCERT Protocol (DIM18) Evaluating Dimebon (Latrepirdine) in Patients with Alzheimer's Disease
Read time: 1 mins
Last updated:17th Jun 2010
To evaluate the long-term safety and tolerability of dimebon (latrepirdine) in Alzheimer�s disease (AD) patients who have completed 52 weeks of blinded treatment in the DIM18 (CONCERT) protocol.
|Study start date||2010-06-17|